18 September 2025
18 September 2025
As the Trump administration distances itself from mRNA technology, promising cancer vaccines could suffer.
The deal is anticipated to close in Q4 2025, subject to customary closing conditions.
The postpartum depression marketing authorisation in the EU follows approvals for the drug in the US and the UK over the past two years.
From a pharmaceutical strategy perspective, zimislecel could anchor a premium, disease-modifying segment in high-risk T1D.
The letter issuances are part of President Trump’s order to stamp out drug adverts that fall short of regulatory standards.
The data de-risks SAB-142’s safety and repeat-dosing profile and broaden its potential across various segments.
In ELSA, children were offered islet autoantibody screening via DBS collection in schools, primary-care clinics, and more.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
